Leica Biosystems Acquires StatLab to Expand Anatomic Pathology Portfolio

Leica Biosystems, a Danaher operating company and global leader in anatomic pathology solutions, has entered into a definitive agreement to acquire StatLab Medical Products, a Texas-based, privately held developer and manufacturer of anatomical pathology products. The acquisition is from Linden Capital Partners and Audax Private Equity. Following the closing, StatLab will become part of Leica Biosystems. Financial terms were not disclosed.

For more than 50 years, StatLab has been a supplier to anatomic pathology laboratories, providing a broad portfolio of products across the pre-analytical and analytical histology workflow. From specimen collection and tissue processing through slide preparation and staining, StatLab’s solutions are designed to help laboratories improve efficiency, standardization, and diagnostic quality. The company has built a reputation for quality, innovation, and customer partnership.

The transaction is anticipated to close by the end of 2026 and is subject to customary conditions, including receipt of applicable regulatory clearances. Following the closing, StatLab will become part of Leica Biosystems.

Gustavo Perez Fernandez, Group Executive of Danaher’s Diagnostics business and President of Leica Biosystems, said the company is excited by the opportunity to combine StatLab’s trusted portfolio with Leica Biosystems’ global leadership in pathology, computational pathology, and AI-enabled diagnostics. He noted that together, the companies can solve some of the hardest problems in healthcare by helping laboratories achieve the consistency, standardization, and quality required to adopt AI-enabled cancer diagnostics at scale. He added that the company looks forward to welcoming the StatLab team and that every step taken to accelerate critical cancer diagnostics helps patients get on the path to treatment faster.

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions, with a mission of “Advancing Cancer Diagnostics, Improving Lives.” The company is a subsidiary of Danaher Corporation. Danaher is a global life sciences and diagnostics innovator focused on improving human health through advanced science and technology, with approximately 60,000 associates worldwide.